A Phase I Trial of Enzastaurin (LY317615) in Patients With Recurrent Gliomas.
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Enzastaurin (Primary)
- Indications Anaplastic astrocytoma; Astrocytoma; CNS cancer; Glioblastoma; Glioma; Oligodendroglioma
- Focus Adverse reactions
- 29 Sep 2011 Planned end date changed from 1 Jan 2006 to 1 Apr 2008 as reported by ClinicalTrials.gov.
- 29 Sep 2011 Planned end date changed from 1 Jan 2006 to 1 Apr 2008 as reported by ClinicalTrials.gov.
- 19 Oct 2007 Status changed from recruiting to in progress.